Eli Lilly (LLY) Long-Term Debt Repayments (2009 - 2026)

Eli Lilly has reported Long-Term Debt Repayments for 17 years, with the latest figure at $750.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Debt Repayments changed N/A year-over-year to $750.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 764100.0% YoY), and the FY2025 full-year result was $778.0 million, up 17.17% from the prior year.
• Long-Term Debt Repayments for Q1 2026 stood at $750.0 million, up from -$100000.0 in the prior quarter.
• The five-year high for Long-Term Debt Repayments was $849.9 million in Q2 2022, with the low at -$200000.0 in Q4 2024.
• Historically, Long-Term Debt Repayments has averaged $514.6 million across 4 years, with a median of $730.0 million in 2022.
• The largest YoY upside for Long-Term Debt Repayments was 50.0% in 2025 against a maximum downside of 50.0% in 2025.
• Eli Lilly's Long-Term Debt Repayments stood at $849.9 million in 2022, then tumbled by 100.02% to -$200000.0 in 2024, then jumped by 50.0% to -$100000.0 in 2025, then jumped by 750100.0% to $750.0 million in 2026.
• The last three Long-Term Debt Repayments figures came in at $750.0 million (Q1 2026), -$100000.0 (Q4 2025), and $778.1 million (Q2 2025), per Business Quant data.